Organization | NEXT Oncology

NEXT Oncology Report issue

For profit Phase 1

Founded: San Antonio TX United States (2019)

Organization Overview

First Clinical Trial

2019

NCT03726294

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

CEO and Founder, NEXT Oncology, | Next Oncology | NEXT Oncology

Active Ingredients

Drugs in Phase 1 Trials (9)

docetaxel (taxotere) (1 trial)

gemcitabine (gemzar) (1 trial)

nbm-bmx (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

ptx-35 (1 trial)

tst001 (1 trial)

ttx-030 (1 trial)

zarnestra (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 5
# of Trial APIs: 9